Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 15, 2021 07:05 ET | Source: Surface Oncology, Inc.

Surface Oncology Appoints Denice Torres as Chair of the Board of Directors

Biopharma veteran Ben Hickey appointed to Board of Directors Lisa McGrath promoted to chief people officer; Shannon Devens promoted to senior vice president, development operations CAMBRIDGE, Mass.,...
December 06, 2021 09:30 ET | Source: Surface Oncology, Inc.

Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
December 03, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Named a 2021 Top Place to Work by the Boston Globe

CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment,...
December 02, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
December 01, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
November 09, 2021 08:10 ET | Source: Surface Oncology, Inc.

Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
November 08, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
November 04, 2021 07:10 ET | Source: Surface Oncology, Inc.

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
November 02, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
October 04, 2021 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

keyboard_arrow_left Previous Page